689TiP NRG Oncology’s GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)

Authors:
  • ZZZ. Zumsteg
    Z. Zumsteg
  • TKT. Karrison
    T. Karrison
  • MIMichaelson
    Michaelson
  • PTP. Tran
    P. Tran
  • RKR. Kudchadker
    R. Kudchadker
  • FFF. Feng
    F. Feng

Abstract
No abstract available